论文部分内容阅读
改变血小板功能的药物使许多动脉疾患和经人工心血管器官修复术的病员减少了血管栓塞性并发症.然而,尽管在动物和临床方面经过广泛的实验研究,血小板拮抗剂的临床适应证仍不清楚.为此本文复习了临床实践中抗血小板药物的现代药理研究.许多体外实验结果常不能用来预测药在体内的抗血小板作用.目前在人类,最常用的血小板功能测定包括出血时间,血小板生存时间,血浆中血小板释放物质βTG和PF_4,以及循环血中血小板聚集量的测定等.抑制花生四烯酸通路的药物:包括能抑制环氧合酶,磷酸脂酶和血栓素合成酶的药物,其中环氧合酶抑制剂包括非类固醇类抗
Drugs that alter platelet function reduce vascular complications in many arterial disorders and in patients undergoing artificial cardiovascular revascularization.However, despite extensive animal and clinical laboratory studies, clinical indications for platelet antagonists remain Clearly, this article reviews modern pharmacological studies of antiplatelet agents in clinical practice, and many of the in vitro results are often not predictive of the antiplatelet effect of the drug in vivo, and in humans the most commonly used platelet function tests include bleeding time, platelets Survival time, release of plasma platelets βTG and PF_4, and determination of platelet aggregation in circulating blood, etc. Drugs that inhibit arachidonic acid pathways include drugs that inhibit cyclooxygenase, phospholipase and thromboxane synthetase Wherein the cyclooxygenase inhibitor comprises a non-steroidal anti-tumor agent